Literature DB >> 16912292

Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes.

Jan Balzarini1, Kristel Van Laethem, Willy J Peumans, Els J M Van Damme, Anders Bolmstedt, Federico Gago, Dominique Schols.   

Abstract

Limited data are available on the genotypic and phenotypic resistance profile of the alpha-(1-2)mannose oligomer-specific prokaryotic lectin cyanovirin (CV-N). Therefore, a more systematic investigation was carried out to obtain a better view of the interaction between CV-N and human immunodeficiency virus type 1 (HIV-1) gp120. When HIV-1-infected CEM cell cultures were exposed to CV-N in a dose-escalating manner, a total of eight different amino acid mutations exclusively located at N-glycosylation sites in the envelope surface gp120 were observed. Six of the eight mutations resulted in the deletion of high-mannose type N-glycans (i.e., at amino acid positions 230, 332, 339, 386, 392, and 448). Two mutations (i.e., at position 136 and 160) deleted a complex type N-glycan in the variable V1/V2 domain of gp120. The level of phenotypic resistance of the mutated virus strains against CV-N generally correlated with the number of glycan deletions in gp120, although deletion of the glycans at N-230, N-392, and N-448 generally afforded a more pronounced CV-N resistance than other N-glycan deletions. However, the extent of the decrease of antiviral activity of CV-N against the mutated virus strains was markedly less pronounced than observed for alpha(1-3)- and alpha(1-6)-mannose-specific plant lectins Hippeastrum hybrid agglutinin (HHA) and Galanthus nivalis agglutinin (GNA), which points to the existence of a higher genetic barrier for CV-N. This is in agreement with a more consistent suppression of a wider variety of HIV-1 clades by CV-N than by HHA and GNA. Whereas the antiviral and in vitro antiproliferative activity of CV-N can be efficiently reversed by mannan, the pronounced mitogenic activity of CV-N on peripheral blood mononuclear cells was unaffected by mannan, indicating that some of the observed side effects of CV-N are unrelated to its carbohydrate specificity/activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912292      PMCID: PMC1563877          DOI: 10.1128/JVI.00369-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping.

Authors:  F Yang; C A Bewley; J M Louis; K R Gustafson; M R Boyd; A M Gronenborn; G M Clore; A Wlodawer
Journal:  J Mol Biol       Date:  1999-05-07       Impact factor: 5.469

Review 2.  Targeting glycosylation as a therapeutic approach.

Authors:  Raymond A Dwek; Terry D Butters; Frances M Platt; Nicole Zitzmann
Journal:  Nat Rev Drug Discov       Date:  2002-01       Impact factor: 84.694

3.  Marked depletion of glycosylation sites in HIV-1 gp120 under selection pressure by the mannose-specific plant lectins of Hippeastrum hybrid and Galanthus nivalis.

Authors:  Jan Balzarini; Kristel Van Laethem; Sigrid Hatse; Matheus Froeyen; Els Van Damme; Anders Bolmstedt; Willy Peumans; Erik De Clercq; Dominique Schols
Journal:  Mol Pharmacol       Date:  2005-02-17       Impact factor: 4.436

4.  Solution structure of cyanovirin-N, a potent HIV-inactivating protein.

Authors:  C A Bewley; K R Gustafson; M R Boyd; D G Covell; A Bax; G M Clore; A M Gronenborn
Journal:  Nat Struct Biol       Date:  1998-07

5.  Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner.

Authors:  A J Bolmstedt; B R O'Keefe; S R Shenoy; J B McMahon; M R Boyd
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

6.  Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120.

Authors:  C A Bewley
Journal:  Structure       Date:  2001-10       Impact factor: 5.006

7.  Crystal structures of the HIV-1 inhibitory cyanobacterial protein MVL free and bound to Man3GlcNAc2: structural basis for specificity and high-affinity binding to the core pentasaccharide from n-linked oligomannoside.

Authors:  David C Williams; Jae Young Lee; Mengli Cai; Carole A Bewley; G Marius Clore
Journal:  J Biol Chem       Date:  2005-06-03       Impact factor: 5.157

8.  Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.

Authors:  Myriam Witvrouw; Valery Fikkert; Anke Hantson; Christophe Pannecouque; Barry R O'keefe; James McMahon; Leonidas Stamatatos; Erik de Clercq; Anders Bolmstedt
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

9.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Site-specific discrimination by cyanovirin-N for alpha-linked trisaccharides comprising the three arms of Man(8) and Man(9).

Authors:  Carole A Bewley; Shigeki Kiyonaka; Itaru Hamachi
Journal:  J Mol Biol       Date:  2002-09-27       Impact factor: 5.469

View more
  45 in total

1.  Microvirin, a novel alpha(1,2)-mannose-specific lectin isolated from Microcystis aeruginosa, has anti-HIV-1 activity comparable with that of cyanovirin-N but a much higher safety profile.

Authors:  Dana Huskens; Geoffrey Férir; Kurt Vermeire; Jan-Christoph Kehr; Jan Balzarini; Elke Dittmann; Dominique Schols
Journal:  J Biol Chem       Date:  2010-05-27       Impact factor: 5.157

2.  Disulfide Sensitivity in the Env Protein Underlies Lytic Inactivation of HIV-1 by Peptide Triazole Thiols.

Authors:  Lauren D Bailey; Ramalingam Venkat Kalyana Sundaram; Huiyuan Li; Caitlin Duffy; Rachna Aneja; Arangassery Rosemary Bastian; Andrew P Holmes; Kantharaju Kamanna; Adel A Rashad; Irwin Chaiken
Journal:  ACS Chem Biol       Date:  2015-10-22       Impact factor: 5.100

3.  The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry.

Authors:  Katrien O François; Jan Balzarini
Journal:  J Biol Chem       Date:  2011-10-17       Impact factor: 5.157

Review 4.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

5.  High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization.

Authors:  Qinxue Hu; Naheed Mahmood; Robin J Shattock
Journal:  Virology       Date:  2007-07-23       Impact factor: 3.616

6.  Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry.

Authors:  Alamelu Mahalingam; Anthony R Geonnotti; Jan Balzarini; Patrick F Kiser
Journal:  Mol Pharm       Date:  2011-09-26       Impact factor: 4.939

7.  Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors.

Authors:  Julie I Jay; Bonnie E Lai; David G Myszka; Alamelu Mahalingam; Kris Langheinrich; David F Katz; Patrick F Kiser
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

Review 8.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

9.  HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity.

Authors:  Nobuyuki Matoba; Adam S Husk; Brian W Barnett; Michelle M Pickel; Charles J Arntzen; David C Montefiori; Atsushi Takahashi; Kazunobu Tanno; Satoshi Omura; Huyen Cao; Jason P Mooney; Carl V Hanson; Haruo Tanaka
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

10.  Mechanism by which the lectin actinohivin blocks HIV infection of target cells.

Authors:  Haruo Tanaka; Harumi Chiba; Junji Inokoshi; Atsushi Kuno; Takahiro Sugai; Atsushi Takahashi; Yukishige Ito; Masaru Tsunoda; Kaoru Suzuki; Akio Takénaka; Takeshi Sekiguchi; Hideaki Umeyama; Jun Hirabayashi; Satoshi Omura
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.